Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SCYX

SCYX - SCYNEXIS Inc Stock Price, Fair Value and News

2.12USD-0.04 (-1.85%)Market Closed

Market Summary

SCYX
USD2.12-0.04
Market Closed
-1.85%

SCYX Stock Price

View Fullscreen

SCYX RSI Chart

SCYX Valuation

Market Cap

81.6M

Price/Earnings (Trailing)

0.81

Price/Sales (Trailing)

0.58

EV/EBITDA

0.44

Price/Free Cashflow

1.09

SCYX Price/Sales (Trailing)

SCYX Profitability

Operating Margin

89.50%

EBT Margin

72.80%

Return on Equity

136.74%

Return on Assets

85.69%

Free Cashflow Yield

92%

SCYX Fundamentals

SCYX Revenue

Revenue (TTM)

140.1M

Rev. Growth (Yr)

282.01%

Rev. Growth (Qtr)

229.38%

SCYX Earnings

Earnings (TTM)

101.3M

Earnings Growth (Yr)

101.21%

Earnings Growth (Qtr)

102.1%

Breaking Down SCYX Revenue

Last 7 days

-6.9%

Last 30 days

6.4%

Last 90 days

44.7%

Trailing 12 Months

-24.9%

How does SCYX drawdown profile look like?

SCYX Financial Health

Current Ratio

3.72

SCYX Investor Care

Shares Dilution (1Y)

3.46%

Diluted EPS (TTM)

2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202338.9M72.6M106.4M140.1M
20221.8M3.1M4.2M5.1M
20215.5M8.0M10.6M13.2M
2020673.0K476.0K311.0K2.9M
2019394.5K532.0K669.5K807.0K
2018483.5K672.5K823.5K257.0K
2017221.0K264.0K325.0K385.5K
2016220.0K195.0K179.0K180.0K
20151.3M1.3M1.3M257.0K
20140001.3M
20130000

Tracking the Latest Insider Buys and Sells of SCYNEXIS Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
sukenick scott
sold (taxes)
-24,741
1.63
-15,179
chief legal officer
Jan 26, 2024
macleod ivor
acquired
-
-
143,675
chief financial officer
Jan 26, 2024
sukenick scott
acquired
-
-
143,675
chief legal officer
Jan 26, 2024
angulo gonzalez david
acquired
-
-
290,590
chief executive officer
Jun 15, 2023
tinmouth brian philippe
acquired
-
-
10,000
-
Jun 15, 2023
gilman steven c
acquired
-
-
10,000
-
Jun 15, 2023
macdonald guy
acquired
-
-
10,000
-
Jun 15, 2023
hanham ann
acquired
-
-
10,000
-
Jun 15, 2023
hastings david c
acquired
-
-
10,000
-
Jun 15, 2023
anido armando
acquired
-
-
10,000
-

1–10 of 50

Which funds bought or sold SCYX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
LRI Investments, LLC
new
-
294
294
-%
May 20, 2024
Virtu Financial LLC
new
-
20,000
20,000
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
137,767
137,767
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
225
12,973
24,310
-%
May 15, 2024
Man Group plc
sold off
-100
-275,287
-
-%
May 15, 2024
Stonepine Capital Management, LLC
reduced
-92.94
-2,881,480
140,586
0.11%
May 15, 2024
Squarepoint Ops LLC
added
405
153,806
219,734
-%
May 15, 2024
Avidity Partners Management LP
unchanged
-
-1,101,030
2,129,630
0.07%
May 15, 2024
CORSAIR CAPITAL MANAGEMENT, L.P.
new
-
69,672
69,672
0.02%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-19.31
-53,985
61,337
-%

1–10 of 48

Are Funds Buying or Selling SCYX?

Are funds buying SCYX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SCYX
No. of Funds

Unveiling SCYNEXIS Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
stonepine capital management, llc
3.6%
1,355,186
SC 13G/A
Feb 13, 2024
caxton corp
0%
0
SC 13G/A
Feb 13, 2024
avidity partners management lp
9.9%
3,968,816
SC 13G/A
Jan 18, 2024
federated hermes, inc.
19.99%
8,094,700
SC 13G/A
Nov 29, 2023
kingdon capital management, l.l.c.
6.02%
2,237,048
SC 13G/A
Jun 09, 2023
stonepine capital management, llc
7.6%
2,777,877
SC 13G
Apr 13, 2023
kingdon capital management, l.l.c.
5.1%
1,697,048
SC 13G
Apr 03, 2023
hirschman orin
3.5%
1,159,346
SC 13G/A
Feb 15, 2023
hirschman orin
5.3%
1,932,046
SC 13G/A
Feb 14, 2023
armistice capital, llc
4.72%
1,618,411
SC 13G/A

Recent SEC filings of SCYNEXIS Inc

View All Filings
Date Filed Form Type Document
May 08, 2024
10-Q
Quarterly Report
Apr 25, 2024
DEFA14A
DEFA14A
Apr 25, 2024
DEF 14A
DEF 14A
Apr 25, 2024
ARS
ARS
Mar 28, 2024
S-8
Employee Benefits Plan
Mar 28, 2024
8-K
Current Report
Mar 28, 2024
10-K
Annual Report

Peers (Alternatives to SCYNEXIS Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.84% -9.54%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.70% 19.17%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-2.39% 35.63%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.74% -31.33%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-4.74% -17.19%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
2.01% 128.69%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
0.53% -21.09%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.64% -15.95%
-484.73
0.82
-0.06% 94.55%
2.3B
9.0B
-11.50% -15.30%
-4.98
0.25
10.01% -27.45%
2.0B
676.2M
-4.53% -14.12%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-11.06% 3.51%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-1.44% -45.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-3.92% -20.33%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.97%
-0.32
0.11
66.16% 61.84%
347.8K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

SCYNEXIS Inc News

Latest updates
MarketBeat30 May 202407:00 am
Yahoo New Zealand News01 May 202411:03 am

SCYNEXIS Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-5,797,0001,760,000131,454,00066,485,7501,517,5001,557,0001,323,000700,000597,000516,000-12,050,0006,027,5005,00036,000147,000123,000170,000233,000281,000
Operating Expenses-62.3%10,881,00028,861,50011,859,00014,940,00011,812,00024,004,50023,358,00023,061,00020,425,00022,893,00019,957,00017,508,00013,644,00015,335,00011,511,00011,826,00012,479,00014,107,50011,756,00011,253,00011,925,000
  S&GA Expenses2.1%3,669,0003,592,0005,014,0007,474,0004,840,00015,902,50016,739,00015,786,00014,591,00015,036,00015,411,00012,774,0006,696,0005,177,5003,481,0003,357,0002,613,0003,147,5002,480,0002,779,0002,241,000
  R&D Expenses-31.9%7,212,00010,586,5006,466,0007,040,0006,835,0007,906,0006,430,0007,131,0005,735,0007,690,0004,401,0004,734,0006,948,00010,157,5008,030,0008,469,0009,866,00010,960,0009,276,0008,474,0009,684,000
EBITDA Margin47.1%0.740.510.730.70-2.19-12.10-18.43-15.47-21.24-2.50-4.46-5.78---------
Interest Expenses-7.7%205,000222,000212,0001,249,0001,447,0001,529,0001,379,0001,231,0001,059,000982,0001,019,000445,000214,000322,000330,000319,000210,000209,500203,000209,000367,000
Income Taxes284.8%531,000138,000-------4,700,000--50,000-4,138,0001,100,000-4,000--3,144,000-----
Earnings Before Taxes104.8%942,000-19,427,000-1,757,000122,260,000-33,876,000-14,420,000-29,584,000-13,345,000-10,151,000-29,243,000-655,000-2,480,000-3,576,000-42,715,000909,000-9,525,000-7,002,000-14,458,000-7,941,000-8,403,000-
EBT Margin51.8%0.730.480.680.61-2.35-13.24-19.71-17.03-23.46-2.73-4.66-5.96---------
Net Income102.1%411,000-19,586,000-1,757,000122,260,000-33,876,000-14,429,000-29,584,000-13,345,000-5,451,000-29,243,000-605,0001,658,000-4,676,000-42,711,000909,000-6,381,000-7,002,000-14,458,000-7,941,000-8,403,000-22,908,000
Net Income Margin51.1%0.720.480.680.61-2.35-12.32-18.58-15.51-18.56-2.50-4.37-5.59---------
Free Cashflow48.2%-4,007,000-7,735,00012,419,00074,398,000-18,923,000-22,806,000-22,508,000-18,581,000-15,988,000-25,520,000-16,586,000-11,695,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.9%11812814915570.0088.0011213611212011012110010337.0045.0042.0057.0034.0041.0045.00
  Current Assets-0.4%10210212914660.0079.0010412610210910411695.0098.0032.0041.0037.0052.0029.0036.0040.00
    Cash Equivalents4.2%35.0034.0044.0058.0027.0046.0069.0011995.0010510011392.0093.0030.0034.0021.0042.0012.0019.0013.00
  Inventory---13.0010.001.001.001.001.001.000.001.000.00---------
  Net PPE---------0.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-20.4%44.0055.0057.0062.0010085.0095.0090.0073.0079.0072.0089.0074.0080.0027.0039.0035.0044.0028.0031.0034.00
  Current Liabilities67.8%27.0016.0017.0016.0046.0018.0014.0016.0013.0014.0013.0020.0025.0026.008.007.007.0011.008.007.005.00
  Long Term Debt----------------------
    LT Debt, Non Current----------------------
Shareholder's Equity1.6%74.0073.0092.0093.00-29.913.0017.0045.0039.0041.0038.0032.0026.0023.0010.006.006.0013.006.0010.0011.00
  Retained Earnings0.1%-354-355-335-333-456-422-407-378-364-359-330-329-331-326-283-284-278-271-256-249-240
  Additional Paid-In Capital0.2%429428428427426425425424404401368362357349293291285284263259252
Shares Outstanding1.5%38.0037.0037.0037.0048.0033.0041.0043.0032.0029.0026.0026.00---------
Float----109,140,501---60.00---169---78.00---70.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations48.2%-4,007-7,73512,41974,398-18,923-22,806-22,508-18,581-15,988-25,520-16,586-11,695-759-16,572-9,869-8,856-14,057-13,458-10,402-7,758-6,501
  Share Based Compensation26.6%7055576327287074541,2101,1009225815885003981,000399411410441449446492
Cashflow From Investing353.4%5,454-2,152-26,341-6,384---27,380--9.00-583-338-51.00-200-3,57110,665-7,76210,044-42110,0206,597
Cashflow From Financing88.9%-15.00-13534.00-36,64222.00--18342,0626,72330,4784,53332,180-71.0080,1191,77111,95915233,7153,2373,9381,415
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SCYX Income Statement

2024-03-31
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 1,373$ 1,130
Operating expenses:  
Cost of product revenues0137
Research and development7,2126,835
Selling, general and administrative3,6694,840
Total operating expenses10,88111,812
Loss from operations(9,508)(10,682)
Other (income) expense:  
Amortization of debt issuance costs and discount401255
Interest income(1,280)(587)
Interest expense2051,447
Warrant liabilities fair value adjustment(9,608)21,673
Derivative liabilities fair value adjustment(168)406
Total other (income) expense(10,450)23,194
Income (loss) before taxes942(33,876)
Income tax expense(531)0
Net income (loss)$ 411$ (33,876)
Net income (loss) per share attributable to common stockholders - basic  
Net income (loss) per share - basic$ 0.01$ (0.71)
Net income (loss) per share attributable to common stockholders - diluted  
Net income (loss) per share - diluted$ 0.01$ (0.71)
Weighted average common shares outstanding – basic and diluted  
Basic48,245,55947,757,246
Diluted48,565,05147,757,246
Product Revenue, Net  
Revenue:  
Total revenue$ 0$ 1,130
License Agreement Revenue  
Revenue:  
Total revenue$ 1,373$ 0

SCYX Balance Sheet

2024-03-31
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 35,482$ 34,050
Short-term investments44,76240,312
Prepaid expenses and other current assets1,5835,548
License agreement receivable02,463
License agreement contract asset19,46619,363
Restricted cash380380
Total current assets101,673102,116
Investments13,94323,594
Deferred offering costs175175
Restricted cash163163
Operating lease right-of-use asset (See Note 7)2,3002,364
Total assets118,254128,412
Current liabilities:  
Accounts payable8,9187,149
Accrued expenses4,6017,495
Deferred revenue, current portion1,0831,189
Operating lease liability, current portion (See Note 7)356340
Warrant liabilities0130
Convertible debt and derivative liability (See Note 6)12,3910
Total current liabilities27,34916,303
Deferred revenue2,1112,727
Warrant liabilities12,20221,680
Convertible debt and derivative liability (See Note 6)012,159
Operating lease liability (See Note 7)2,4872,581
Total liabilities44,14955,450
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 37,779,796 and 37,207,799 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively4140
Additional paid-in capital428,900428,169
Accumulated deficit(354,836)(355,247)
Total stockholders' equity74,10572,962
Total liabilities and stockholders’ equity$ 118,254$ 128,412
SCYX
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
 CEO
 WEBSITEscynexis.com
 INDUSTRYPharmaceuticals
 EMPLOYEES36

SCYNEXIS Inc Frequently Asked Questions


What is the ticker symbol for SCYNEXIS Inc? What does SCYX stand for in stocks?

SCYX is the stock ticker symbol of SCYNEXIS Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SCYNEXIS Inc (SCYX)?

As of Wed Jun 12 2024, market cap of SCYNEXIS Inc is 81.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers. The fair value of SCYNEXIS Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SCYNEXIS Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SCYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SCYNEXIS Inc a good stock to buy?

The fair value guage provides a quick view whether SCYX is over valued or under valued. Whether SCYNEXIS Inc is cheap or expensive depends on the assumptions which impact SCYNEXIS Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCYX.

What is SCYNEXIS Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, SCYX's PE ratio (Price to Earnings) is 0.81 and Price to Sales (PS) ratio is 0.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SCYNEXIS Inc's stock?

In the past 10 years, SCYNEXIS Inc has provided -0.312 (multiply by 100 for percentage) rate of return.